Cystectomy in the elderly patient.

[Cystectomy in the elderly patient.] Urologe A. 2013 Apr 21; Authors: Bartsch G, Gust K, Vallo S, Bartsch C, Tsaur I, Mani J, Haferkamp A Abstract Bladder cancer is a carcinoma of the elderly population. The highest incidence of bladder cancer is between the ages of 70 and 80 years old. Radical cystectomy remains the gold standard for muscle invasive bladder cancer treatment. In this article different aspects of radical cystectomy in elderly patients are reviewed. The Pubmed-MEDLINE database was searched using the following keywords: radical, cystectomy, elderly and age. PMID: 23604451 [PubMed - as supplied by publisher]
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research

Related Links:

ConclusionsCT-based radiomics prediction model can evaluate muscle invasiveness of bladder cancer before surgery with a good diagnostic performance.Key Points•CT-based radiomics model can evaluate muscle invasive status in bladder cancer.•The radiomics model shows good diagnostic performance to differentiate muscle-invasive bladder cancer from non-muscle-invasive bladder cancer.•This preoperative CT-based prediction method might complement MR evaluation of bladder cancer and supplement biopsy.
Source: European Radiology - Category: Radiology Source Type: research
Conditions:   Urothelial Carcinoma;   Bladder Cancer Intervention:   Drug: Ipilimumab + nivolumab Sponsors:   The Netherlands Cancer Institute;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: In observational analyses designed to emulate the SPARE trial, there was no statistically significant difference in OS between RC and TMT. Heterogeneity of treatment effects suggested improved survival with RC only for cT3 disease.PMID:35058142 | DOI:10.1016/j.urolonc.2021.12.015
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Source Type: research
CONCLUSIONS: Residual CIS-only after NAC and RC demonstrated similar survival outcomes when compared to patients with pathologic CR. Further study in large multi-institutional cohorts may further validate CIS-only as an additional surrogate endpoint after NAC and may inform future trials.PMID:35045949 | DOI:10.1016/j.urolonc.2021.11.021
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Source Type: research
Telomerase reverse transcriptase (TERT) promoter mutations, resulting in increased TERT activity, are known to be associated with many different cancer types, including among 70%–80% of glioblastomas and 60% each of bladder carcinomas and hepatocellular carcinomas.1–3 Increased TERT activity has also been associated with several molecular features including rare rearrangements, duplications and amplifications.1 However, of all the molecular changes, mutations in the TERT promoter region are known to be the most frequent. They are often restricted to two hotspots, 124 and 146 base pairs upstream of the transcrip...
Source: Journal of Clinical Pathology - Category: Pathology Authors: Tags: PostScript Source Type: research
Drug Discov Ther. 2021;15(6):331-336. doi: 10.5582/ddt.2021.01108.ABSTRACTUrinary Bladder cancer (UBC) is a diversified disease with an array of clinicopathological attributes. Several studies have shown that cancer susceptibility candidate 5 (CASC5) plays important roles in various types of malignancies; however its expression and clinical significance in human UBC remain largely unknown. This research study was intended to explore mRNA/protein expression pattern of CASC5 as a member of the cancer-testis (CT) gene family and assess its clinical utility in diagnostic management of patients with UBC. Quantitative real-time ...
Source: Drug Discoveries and Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research
ConclusionHIVEC provides comparable safety and efficacy to BCG and is a reasonable alternative during BCG shortages.Trial registrationEudraCT 2016-001186-85. Date of registration: 17 March 2016.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Rationale: Routine neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma prior to radical surgery is curative. With the increase in cancer immunotherapy, neoadjuvant immunotherapy has been used as an important complement to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Toripalimab is a recombinant, humanized IgG4 monoclonal antibody directed against programmed cell death protein 1 and received the first global approval for the treatment of unresectable or metastatic melanoma in China on December 17, 2018. Patient concerns and diagnosis: A 57-year-old man was admitted to our ho...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
ConclusionThese data provide preclinical evidence that dysregulated MED10/MIR590 signaling drives onco-aggression, disease progression, and recurrence of bladder UC and that this oncogenic signal is therapeutically actionable for repressing the metastatic/recurrent phenotypes, enhancing therapy response, and shutting down stemness-driven disease progression and relapse in patients with BLCA/UC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionSynchronous UC of the urinary bladder is an independent adverse prognostic factor for survival in UTUC. The presence of preoperative hydronephrosis was also corroborated as a disadvantageous prognostic factor. Our multivariate analysis suggested that laparoscopic RNU might provide better oncological control.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Urology & Nephrology